Table 1.

Multicovariate Cox model fitted to estimate the effects of age, gender, disease stage, institution, and EphA4 expression on time to death or relapse

CovariatesHR95% CIP
Overall survival (N = 422)
 Low vs. high EphA41.571.13–2.180.007
Moderate vs. high EphA40.980.70–1.390.922
Age1.041.02–1.05<0.001
Male vs. female1.270.96–1.670.090
Stage III vs. I-II4.273.05–5.98<0.001
Moffitt Cancer Center1.560.99–2.470.057
MI0.870.57–1.330.520
MSKCC0.610.37–1.010.053
Relapse-free survival (N = 327)
 Low vs. high EphA41.461.01–2.110.045
Moderate vs. high EphA41.180.81–1.720.388
Age1.011.00–1.030.092
Male vs. female1.080.80–1.470.608
Stage III vs. I-II2.471.63–3.74<0.001
Moffitt Cancer Center0.990.62–1.560.949
MI0.670.43–1.040.074
MSKCC0.570.36–0.900.016

NOTE: EphA4 expression was stratified using tertiles, and 3 groups with high, moderate, or low levels of EphA4 expression were compared (19). 95 CI, 95% confidence interval; P-value was from the Wald test.

Abbreviations: MI, University of Michigan Cancer Center; MSKCC, Memorial Sloan Kettering Cancer Center.